Bellos Themistoklis Ch, Tzelves Lazaros I, Manolitsis Ioannis S, Katsimperis Stamatios N, Berdempes Marinos V, Skolarikos Andreas, Karakousis Nikolaos D
2nd Department of Urology, Sismanoglio General Hospital of Athens, Athens, Greece.
Primary Healthcare, Internal Medicine Department, Amarousion, Attica, Greece.
Maedica (Bucur). 2022 Jun;17(2):427-435. doi: 10.26574/maedica.2022.17.2.427.
Sarcopenia, defined as the systemic loss of muscle function and mass, is commonly seen in advanced oncologic states, usually in conjunction with cancer cachexia. Bladder cancer represents one of the most common neoplasms worldwide and affects mainly the elderly who are already frail. The purpose of this study is to review the potential association between sarcopenia and bladder cancer in patients receiving different types of treatments. A thorough MEDLINE/PubMed non-systematic literature review was conducted from 1990 to January 2022, using the following search terms: "sarcopenia and bladder cancer" and "low muscle mass and bladder cancer". Sarcopenia probably poses a negative impact on the prognosis of patients at any stage of bladder cancer, as it is linked with overall worse survival, cancer specific survival and progression-free survival in those treated, with either radical cystectomy or chemotherapy. In addition, sarcopenia seems to be a strong predictor concerning complications and a negative prognostic factor following chemotherapy and surgery for bladder cancer. On the other hand, it seems that sarcopenic patients who receive radiotherapy or immunotherapy are not so severely affected.
肌肉减少症被定义为肌肉功能和质量的全身性丧失，常见于晚期肿瘤状态，通常与癌症恶病质同时出现。膀胱癌是全球最常见的肿瘤之一，主要影响已经体弱的老年人。本研究的目的是回顾接受不同类型治疗的膀胱癌患者中肌肉减少症与膀胱癌之间的潜在关联。我们使用以下检索词，对1990年至2022年1月的MEDLINE/PubMed进行了全面的非系统性文献综述：“肌肉减少症与膀胱癌”以及“低肌肉量与膀胱癌”。肌肉减少症可能对膀胱癌任何阶段患者的预后产生负面影响，因为在接受根治性膀胱切除术或化疗的患者中，它与总体生存率、癌症特异性生存率和无进展生存率较差相关。此外，肌肉减少症似乎是膀胱癌化疗和手术后并发症的一个强有力预测指标以及不良预后因素。另一方面，接受放疗或免疫治疗的肌肉减少症患者似乎受影响没那么严重。
